Skip to main content

Advertisement

Table 3 Effect of radiation on local invasion or metastasis of rodent and human cancer cell lines as tested in syngeneic and in xenogeneic mice respectively

From: Effects of radiation on the metastatic process

Radiation    Inoculum    Score (Ir/Ctrl) Molecular Ref
Target Mode Dose Code Origin Site    
     Syngeneic     
Cancer cells
  137 Cs 3 Gy 9 L glioma intracaranial 40d αvβ3 (Wild-Bode et al., 2001)
  C-ion 5 Gy LM8 osteosarcoma subcutaneous 0.6   (Ogata et al., 2005)
  C-ion 5 Gy LM8 osteosarcoma intravenous 0.4   (Ogata et al., 2005)
  4 MV 10 Gy LM8 osteosarcoma subcutaneous 1   (Ogata et al., 2005)
  4 MV 10 Gy LM8 osteosarcoma intravenous 0.4   (Ogata et al., 2005)
  nm 3 Gy 9 L glioma intracaranial 2.4d IGFR1 (Zhai et al., 2006a)
CAF
  137 Cs 10 Gy Suit_2/CAF pancreatic ca intrapancreas 2.5d Met (Ohuchida et al., 2004)
  nm 4 Gy PC/CAFCM Pancreatic ca intravenous 4 CXCL12 (Li et al., 2016a)
Mammary f. p.
  MV 4 × 6 Gy D2A1/FUCCI mammary ca mammary f.p. 1.8d COX2; IL6 (Bouchard et al., 2013)
  MV 4 × 6 Gy D2A1/FUCCI mammary ca mammary f.p. 2c   (Bouchard et al., 2013)
  MV 4 × 6 Gy D2A1/FUCCI mammary ca mammary f.p. 2.4   (Bouchard et al., 2013)
  MV 4 × 6 Gy D2A1/FUCCI mammary ca intravenous 1   (Bouchard et al., 2013)
  125 kV 20 Gy AT1 mammary ca mammary f.p. 6d HIF/KITL (Kuonen et al., 2012b)
  125 kV 20 Gy AT1 mammary ca mammary f.p. 8b   
  125 kV 20 Gy AT1 mammary ca mammary f.p. 6   
Thorax
  300 kV 10 Gy MMT/PyVmT mammary ca intravenous 4 TGFβ (Biswas et al., 2007)
  300 kV 10 Gy MMT/PyVmT mammary ca mammary f.p. 17c TGFβ (Biswas et al., 2007)
  300 kV 10 Gy MMT/PyVmT mammary ca mammary f.p. 17 TGFβ (Biswas et al., 2007)
  60 Co 1 × 15 Gy TS/A mammary ca intravenous 2.5   (Klein et al., 2016)
  60 Co 1 X15 Gy B16/F10 melanoma intravenous 2.3 uPA;CCL2  
Partial lung
  220 kV 10 Gy 4 T1 mammary ca mammary f.p. 3   (Feys et al., 2015)
Abdomen
  6 MeV 2 Gy CT26 colon ca intravenous > 1   (Timaner et al., 2015)
Total Body
  60 Co 10 Gy B16/F10 melanoma subcutaneous 2   (Klein et al., 2016)
Tumor
  250 kV 10 × 0.6 Gy KLN-205 sarcoma subcutaneous 1a   (Baker et al., 1981)
  137 Cs 5 × 10 Gy LLC-LM lung ca subcutaneous 10   (Camphausen et al., 2001)
  137 Cs 5 × 10 Gy T241 fibrosarcoma subcutaneous 14 angiosatin (Camphausen et al., 2001)
  6 MV 8 Gy ALT-S1C1 glioma intracranial 0.7   (Wang et al., 2013)
  60Co 5 × 10 Gy LLC-M lung ca subcutaneous 5 MMP9 (Chou et al., 2012)
     Xenogeneic     
Cancer cells
  60Co 7.5 Gy HepG2 Hepatoma intrahepatic 3d MMP9 (Cheng et al., 2006a)
  60Co 4 Gy CHO1 Fibrosarcoma intravenous 5   (Hamalukic et al., 2011a)
  MV 6 Gy CaSki Cervical ca intravenous 1.6 Ras (Su et al., 2012)
  MV 2 Gy HT1299 Lung ca intravenous 6a CXCR4 (Gu et al., 2015a)
Inoculation site
  220 kV 20 Gy R18 Melanoma intradermal 2b O2/uPAR (Rofstad et al., 2005)
  220 kV 20 Gy D12 Melanoma intradermal 2 O2/IL8 (Rofstad et al., 2005)
  220 kV 20 Gy SCCVII Oral ca subcutaneous 3.5 CYR61; αvβ5 (Monnier et al., 2008)
  220 kV 20 Gy HCT116 Colon ca subcutaneous 4   
Total body
  6 MV 0.3 Gy 4 T1 mammary ca mammary f.p. 7 VEGFR (Sofia Vala et al., 2010)
  6 MV 0.3 Gy MOLT4 leukemia intravenous 5   
Tumor
  220 kV 10 Gy R18 Melanoma intradermal 1.6b O2/uPAR (Rofstad et al., 2004)
  250 kV 2 × 4 Gy U251 glioma intracranial > 1d MMP2 (Badiga et al., 2011)
  60Co 5 × 10 Gy C6L glioma subcutaneous > 1a EMT (Park et al., 2012)
  nm 5 × 2 Gy FCT133 Thyroid ca subcutaneous 1.6 PI3K (Burrows et al., 2013)
  nm 20 Gy 4 T1 mammary ca mammary f.p. 5e   (Vilalta et al., 2014)
  6 MeV 2 Gy SW480 Colon ca intracolonic > 1a   (Timaner et al., 2015)
  X-rays 15 × 2 Gy SGC7901 Gastric ca subcutaneous 2   (Zhang et al., 2015a)
  1. Scores indicate the metastasis in the lungs unless indicated as: a, lung and other metastases; b, lymph node metastasis; c, circulating tumor cells (CTC); d, Local invasion; e, self-seeding from an unirradiated heterolateral breast tumor to an irradiated recipient one. Scores represent metastasis after administration of radiation relative to control mice (Ir/Ctrl). Abbreviations; avb3, integrin; CAF, cancer-associated fibroblasts; C-ion, carbon-ions; Ca, carcinoma; CAF, cancer-associated fibroblasts; CCL2, C-C motif chemokine ligand 2; CM, conditioned medium; Co, cobalt; COX-2, cyclooxygenase-2; Cs, cesium; CTC, circulating tumor cells; CXCL12, C-X-C motif chemokine 12; CXCR4, C-X-C chemokine receptor type 4; CYR61, Cysteine-rich angiogenic inducer 61; EMT, epithelial-to-mesenchymal transition; f.p., fat pad; Gy, gray; HIF, hypoxia-inducible factor; IGFR, insulin-like growth factor receptor; IL, interleukin; KITL, tyrosine-kinase receptor encoded by the KIT locus, also known as stem cell factor; Met, tyrosine-protein kinase Met; MMP, matrix metalloproteinases; nm, not mentioned; PI3K, phosphatidylinositol 3-kinase; Ras, small GTPase encoded by the RAS gene; sa, sarcoma; TGF-b, transforming growth factor beta; uPAR, urokinase-type plasminogen activator receptor; VEGFR, vascular endothelial growth receptor